Bilcare Ltd
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
- Market Cap ₹ 144 Cr.
- Current Price ₹ 61.0
- High / Low ₹ 116 / 52.9
- Stock P/E 13.3
- Book Value ₹ 180
- Dividend Yield 0.00 %
- ROCE 1.58 %
- ROE 0.51 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.34 times its book value
- Debtor days have improved from 143 to 82.3 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -41.0% over past five years.
- Promoter holding is low: 30.0%
- Company has a low return on equity of -1.65% over last 3 years.
- Contingent liabilities of Rs.714 Cr.
- Earnings include an other income of Rs.22.1 Cr.
- Working capital days have increased from 675 days to 1,530 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 401 | 331 | 315 | 286 | 258 | 240 | 212 | 304 | 430 | 14 | 18 | 15 | 10 | |
| 337 | 310 | 300 | 288 | 258 | 239 | 219 | 279 | 393 | 21 | 27 | 21 | 16 | |
| Operating Profit | 64 | 21 | 15 | -3 | -0 | 1 | -8 | 25 | 37 | -7 | -9 | -6 | -6 |
| OPM % | 16% | 6% | 5% | -1% | -0% | 0% | -4% | 8% | 9% | -51% | -52% | -38% | -62% |
| 30 | 4 | -106 | 74 | 260 | 6 | 38 | 67 | 43 | 515 | 19 | 18 | 22 | |
| Interest | 147 | 132 | 32 | 48 | 56 | 72 | 69 | 75 | 68 | 0 | 2 | 4 | 1 |
| Depreciation | 68 | 106 | 101 | 79 | 304 | 248 | 88 | 35 | 35 | 5 | 2 | 3 | 3 |
| Profit before tax | -120 | -212 | -223 | -56 | -101 | -314 | -127 | -18 | -24 | 503 | 6 | 5 | 13 |
| Tax % | 1% | -13% | -65% | 17% | -21% | 0% | -19% | -110% | -24% | 22% | 6% | 27% | |
| -121 | -184 | -78 | -66 | -80 | -315 | -102 | 2 | -18 | 391 | 5 | 4 | 11 | |
| EPS in Rs | -51.59 | -78.01 | -33.22 | -28.00 | -33.95 | -133.89 | -43.46 | 0.76 | -7.55 | 165.97 | 2.27 | 1.70 | 4.54 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -27% |
| 5 Years: | -41% |
| 3 Years: | -67% |
| TTM: | -36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 15% |
| 3 Years: | 27% |
| TTM: | 317% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | 6% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | -29% |
| 5 Years: | -10% |
| 3 Years: | -2% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 831 | 643 | 599 | 533 | 453 | 138 | 36 | 37 | 20 | 387 | 392 | 396 | 401 |
| 1,228 | 1,151 | 976 | 898 | 857 | 868 | 709 | 678 | 690 | 8 | 10 | 11 | 12 | |
| 554 | 802 | 441 | 518 | 285 | 346 | 205 | 189 | 193 | 36 | 35 | 22 | 22 | |
| Total Liabilities | 2,636 | 2,621 | 2,039 | 1,973 | 1,618 | 1,375 | 973 | 928 | 927 | 454 | 460 | 452 | 458 |
| 1,255 | 1,217 | 1,177 | 1,147 | 844 | 594 | 506 | 473 | 446 | 16 | 63 | 61 | 61 | |
| CWIP | 182 | 125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 683 | 682 | 553 | 553 | 514 | 513 | 173 | 89 | 81 | 294 | 294 | 294 | 294 |
| 517 | 596 | 310 | 272 | 260 | 268 | 293 | 366 | 400 | 144 | 104 | 98 | 104 | |
| Total Assets | 2,636 | 2,621 | 2,039 | 1,973 | 1,618 | 1,375 | 973 | 928 | 927 | 454 | 460 | 452 | 458 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 | -17 | 28 | 37 | 7 | 62 | 71 | -0 | 46 | 397 | 98 | 2 | |
| -31 | -14 | 9 | -48 | 78 | 2 | 11 | 85 | 6 | 181 | -107 | 3 | |
| -153 | 23 | -35 | 6 | -87 | -60 | -83 | -82 | -55 | -571 | -1 | -4 | |
| Net Cash Flow | -7 | -9 | 2 | -5 | -1 | 3 | -1 | 2 | -4 | 7 | -10 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 80 | 69 | 62 | 58 | 56 | 67 | 87 | 79 | 247 | 101 | 82 |
| Inventory Days | 153 | 215 | 85 | 51 | 51 | 68 | 57 | 85 | 71 | 60 | 21 | 30 |
| Days Payable | 165 | 181 | 77 | 86 | 114 | 156 | 129 | 116 | 100 | 439 | 91 | 154 |
| Cash Conversion Cycle | 83 | 114 | 77 | 27 | -5 | -31 | -5 | 56 | 50 | -132 | 31 | -42 |
| Working Capital Days | -212 | -328 | -460 | -556 | -295 | -396 | -356 | -178 | -134 | -641 | 1,135 | 1,530 |
| ROCE % | -0% | -4% | -4% | -5% | -21% | -20% | -9% | 0% | 2% | -1% | -2% | 2% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Newspaper publication of Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended 31st December, 2025.
-
Exercise Of Right Of Conversion Of Convertible Warrants
12 Feb - Approved Q3/9M results; convert 1,870,000 warrants raising Rs28.05 crore; CIL to redeem 28,050,000 pref shares by 31 Mar 2026.
-
Redemption Of Preference Shares
12 Feb - Board approved Q3 results; CIL to redeem Rs28.05 crore; Bilcare to convert 1.87m warrants paying Rs28.05 crore.
-
Unaudited Financials Result (Standalone And Consolidated) For The Quarter And Nine Months Ended 31.12.2025 Along With Limited Review Report.
12 Feb - Board approved Q3/9M results; Bilcare converting 1.87M warrants, CIL redeeming shares; Rs28.05 crore; auditor flagged Rs14.42 crore.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 12 February 2026.
12 Feb - Board approved Q3/9M FY26 results; Rs14.42 Cr CSIR issue; Rs28.05 Cr conversion and redemption by Mar31,2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services offered:
a) Pharma Packaging:[1]
Pharma Packaging is available in two broad categories viz., Polymer based Packaging Films and Aluminum based Packaging Foils. Their sub-categories are:
Blister Films
Blister Foils
Lidding Foils
CR Foils
Laminates
b) Global Clinical Supplies and Services:[2]
Company handles domestic and global manufacturing of IMPs and Placebos, Primary
and secondary packaging with various blinding techniques, IWRS, Storage at variable temperatures.